Stockwinners Market Radar for July 17, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:46 EDT Splunk announces Splunk Edge Hub - Splunk announced Splunk Edge Hub, a new solution that simplifies the ingestion and analysis of data generated by sensors, IoT devices and industrial equipment. Unveiled at .conf23, Splunk Edge Hub provides more complete visibility across IT and OT environments by streaming previously hard to access data directly into the Splunk platform. Supported by Splunk partner solutions and optimized to work with the Splunk platform's predictive analytics, Splunk Edge Hub enables advanced monitoring, investigation and response to help organizations drive digital resilience across their systems.

19:58 EDT Meta CEO Zuckerberg 'very optimistic' about early Threads engagement - Meta CEO Mark Zuckerberg said in a Thread, "I'm very optimistic about how the Threads community is coming together. Early growth was off the charts, but more importantly 10s of millions of people now come back daily. That's way ahead of what we expected. The focus for the rest of the year is improving the basics and retention. It'll take time to stabilize, but once we nail that then we'll focus on growing the community. We've run this playbook many times (FB, IG, Stories, Reels, etc) and I'm confident Threads is on a good path too." Reference Link

18:27 EDT Ross Stores opens 27 new locations - Ross Stores recently opened 18 Ross Dress for Less and nine dd's DISCOUNTS stores across 14 different states in June and July. These new locations are part of the Company's plans to add approximately 100 new stores - 75 Ross and 25 dd's DISCOUNTS - during fiscal 2023. "These recent openings reflect our ongoing plans to continue building our presence in both existing and newer markets," said Gregg McGillis, Group Executive Vice President, Property Development. "This summer, Ross Dress for Less opened its inaugural six stores in the state of Michigan and dd's expanded its presence in Arizona, California, Florida, Georgia, Oklahoma, and Pennsylvania. Looking ahead, we remain confident in our ability to grow to at least 2,900 Ross Dress for Less and 700 dd's DISCOUNTS locations over time."

18:08 EDT Coinbase 'aware' some customers experiencing 'degraded performance' - Coinbase said, "Our teams are aware that some customers may be experiencing degraded performance for Coinbase Simple Trade (buy and sell). We're working on a fix and will provide an update here and on our Statuspage ASAP." Reference Link

17:29 EDT TDS Telecom provides update on the amount of lead-covered cables - In response to recent media reporting, TDS Telecommunications , a subsidiary of Telephone and Data Systems, conducted an assessment of its communications network across the country and located approximately 10 miles of lead-covered cables. TDS Telecom is identifying next steps to address the very limited amount of lead cabling it estimates is in its network. TDS Telecom strives to follow all applicable local, state, and federal laws where it provides service.

17:10 EDT Silvercorp reports high-grade silver-lead intercepts from TLP mine in China - Silvercorp Metals reports high-grade silver-lead intercepts from its ongoing diamond drilling program at the TLP mine at the Ying Mining District, China....Surface hole ZKTDB0413 intersected 1,025 grams per tonne silver elevation. From January 1, 2022, to June 15, a total of 66,679 m in 340 diamond drill holes, including 270 underground holes and 70 surface holes, were completed at the TLP mine. Assay results for 227 holes have been received, with 197 holes intersecting mineralization. Currently, there are 10 rigs drilling at the TLP mine. The drilling program has targeted three areas: 1 silver-lead vein structures in the resource area at higher elevations, close to surface, which have seen limited exploration; 2 infilling in the production area, particularly above or below previously-mined stopes, where production stopped due to higher than modelled variability in grades, thicknesses, and attitudes of the vein structures; and 3 step out drilling to test the extension of the major vein structures to the northeast of the resource area.

17:02 EDT BlackRock names Saudi Aramco CEO Nasser to board of directors - BlackRock announced that it is naming the Chief Executive Officer of the Saudi Arabian Oil Company to BlackRock's Board of Directors, while also preparing for the departure of a Board member. Amin Hassan Ali Nasser, President and Chief Executive Officer of Aramco, joins the Board today as an independent director. Bader M. Alsaad, Director General and Chairman of the Board of the Arab Fund for Economic & Social Development, will serve the remainder of his term this year and will not stand for reelection to the Board in 2024. The continuity of regional expertise on BlackRock's Board reflects the importance of the Middle East to the firm's long-term strategy. Nasser oversaw the successful public listing of Aramco, which was the largest IPO in history.

16:55 EDT Dell Technologies' Allison Dew sells over $18M in company shares - Officer of Dell Allison Dew disclosed the sale of 329,038 shares of company stock at $55.24 per share for a total transaction amount of $18,176,717.

16:39 EDT Colliers: Normal course issuer bid accepted for up to 10% of float - Colliers International Group announced that the Toronto Stock Exchange has accepted a notice filed by Colliers of its intention to make a normal course issuer bid with respect to its outstanding subordinate voting shares The notice provides that Colliers may, during the twelve month period commencing July 20 and ending no later than July 19, 2024, purchase through the facilities of the TSX, alternative Canadian Trading Systems or The NASDAQ Stock Market up to 4,000,000 Subordinate Voting Shares in total, being approximately 10% of the 40,066,978 shares comprising the "public float" as of July 17, of such class of shares.

16:36 EDT Masimo to take actions to reduce costs in 2H23 - The company said, "With second quarter revenues below expectations, the Company is taking actions to reduce costs in the second half of the year. Management will share more details on these actions when the company announces complete second quarter 2023 financial results on Tuesday, August 8, 2023. Despite the second quarter revenue shortfall, the fundamentals of both businesses remain strong. Notably, on the healthcare side, new hospital customers continue to switch to Masimo technology faster than ever, increasing Masimo's share of the hospital market. Masimo drove record contracting in the first half of the year, both in the U.S. and worldwide. Masimo's Unrecognized Contract Revenue (as defined in Masimo's Annual Report on Form 10-K filed March 1, 2023) is expected to range from $1.37 billion to $1.38 billion at the end of the second quarter, representing growth of 11% to 12% in Unrecognized Contract Revenue versus the end of the second quarter of 2022. On the consumer side, it is unclear when the softness in the premium and luxury categories will improve. However, initial demand for the Stork baby monitor has been strong, as major retailers are placing stocking orders for the product. In addition, hearables sales doubled this quarter versus the same quarter last year, helped by the launch of the Denon PerL earbuds with Masimo AAT... Management plans to discuss Masimo's complete second quarter 2023 financial results and provide updated fiscal year 2023 financial guidance after the market closes on Tuesday, August 8, 2023. We currently expect to reduce the lower end of full year revenue guidance for the healthcare business to $1.30 billion from $1.45 billion. We are still evaluating the upper end of revenue guidance for the healthcare business, but it could be materially higher than the lower end of the range, as we are still targeting our original guidance. We also expect to reduce annual revenue guidance for the non-healthcare business to $800 million to $850 million from $965 million to $995 million."

16:33 EDT Endo partners with Premier to address Pitocin shortage - Endo International (ENDP) and Premier (PINC) announced that Endo's Par Sterile Products business will supply Pitocin vials through Premier's ProvideGx and PremierProRx programs. Pitocin is used to induce labor in pregnant women. The product is on the World Health Organization's essential medications list and has a history of supply disruptions, which can result in potential health risks to mothers and babies, as well as costly delays in hospital labor and delivery wards. The partnership involves a multifaceted approach seeking to provide stable product supply through adequate safety stock on a long-term basis.

16:32 EDT FactSet appoints Catrina Harding as chief people officer - FactSet announced the appointment of Catrina Harding as executive VP, chief people officer, effective July 17. In this role, she will oversee FactSet's global human resources organization and report directly to CEO Phil Snow. Harding brings over 20 years of experience in senior human resources roles at major global companies.

16:31 EDT Advance Auto Parts expresses no opinion on TRC's 'mini-tender' offer - Advance Auto Parts has been notified that TRC Capital Investment Corporation has made an unsolicited "mini-tender" offer to purchase up to 1,000,000 shares of Advance Auto Parts stock at $65.75 per share, or 4.43 percent below the closing price of the company's stock on July 10, 2023, the last trading day before the date of the offer. As of today, TRC offer price is 6.9 percent below the closing price of the company's stock on July 14, 2023. Advance Auto Parts is in no way associated with TRC and expresses no opinion on TRC's "mini-tender" offer. Mini-tender offers seek to acquire less than five percent of a company's outstanding shares, thereby avoiding many disclosure and procedural requirements under U.S. federal securities laws and the rules and regulations of the U.S. Securities and Exchange Commission. As a result, mini-tender offers do not provide investors with the same level of protections as provided by larger tender offers under the U.S. federal securities laws.

16:25 EDT IronNet to voluntarily delist securities from NYSE - IronNet announced its intention to voluntarily delist from the New York Stock Exchange. This announcement follows the company's receipt of notice from the NYSE that the company is not in compliance with the NYSE's continued listing standards. The company has been evaluating its options with respect to its NYSE listing. After discussions and deliberations on these matters, the company's board of directors has approved a resolution authorizing the company to voluntarily delist from the NYSE.

16:21 EDT Vertiv Holdings managing director O'Doherty sells 137,206 class A shares - In a regulatory filing, Vertiv managing director Philip O'Doherty disclosed the sale of 137,206 class A common shares of the company on July 13 at a price of $27 per share.

16:18 EDT Berry Corporation to acquire Macpherson Energy for $70M in cash - Berry Corporation announced that it has executed a definitive agreement to acquire Macpherson Energy Corporation, a privately held Kern County, California operator, for $70M in cash, subject to customary purchase price adjustments. The transaction is structured such that $50M will be paid at closing and the remainder paid in July 2024. This is a value creating transaction for Berry and our shareholders that we expect to be fully paid for by mid-year 2024 based on current projections for the pro forma company and $75/barrel Brent pricing. Substantially all of the purchase price will come from reallocating $35M of Berry's planned 2023 capital expenditures and the free cash flow expected from the acquired production. The free cash flow generated by the proforma company, after the transaction is fully paid in 2024, is expected to be 15% to 25% greater than Berry standalone, which will enhance returns to Berry's shareholders. This transaction is consistent with Berry's shareholder return model, which provides that 20% of annual post-fixed dividend adjusted free cash flow will be returned to shareholders through variable dividends and the remaining 80% will be used for stock and debt repurchases, as well as bolt-on acquisitions such as this one. This acquisition is expected to close in the third quarter, subject to customary terms and conditions. Management will update its FY23 guidance in connection with the acquisition closing.

16:14 EDT Larimar Therapeutics CMO Nancy Ruiz retires, Russell Clayton succeeds - Larimar Therapeutics announced the appointment of Russell Clayton as chief medical officer, or CMO, effective immediately. Clayton succeeds former CMO Nancy Ruiz, who is retiring and will provide consulting support to the company as needed.

16:12 EDT 4D Molecular completes enrollment of 50 patients in dose expansion of trial - 4D Molecular Therapeutics announced that it has completed enrollment of the Phase 2 Dose Expansion stage of the PRISM clinical trial for patients with wet age-related macular degeneration or wet AMD over approximately two quarters, and that no significant 4D-150 safety events or inflammation have been reported to date. "The rapid enrollment of the Phase 2 Dose Expansion stage of the PRISM trial is indicative of the high demand by wet AMD patients and physicians for a new safe and effective therapy delivered by routine outpatient intravitreal injection with the potential to significantly reduce the need for frequent anti-VEGF injections," said Robert Kim, M.D., Chief Medical Officer of 4DMT. "We thank the PRISM investigators and patients for their enthusiasm for this important study as we rapidly advance 4D-150 towards the next stage of development. As of July 3 for patients enrolled in Dose Expansion with maximum follow-up through 20 weeks, no treatment-emergent Grade greater than or equal to1 inflammatory cells or required deviations from the 20-week protocol-specified corticosteroid eyedrop taper were reported. In addition, no hypotony, no vasculitis and no treatment-related serious adverse events were reported. We expect to have initial discussions with the FDA on Phase 3 pivotal trial design for 4D-150 for patients with wet AMD in Q4 2023, and we expect to provide an update on pivotal trial plans in Q1 2024...We expect to enroll our first patient in the Phase 2 SPECTRA trial in Q3 2023. We remain committed to the advancement of our large market ophthalmology product candidates, including 4D-150 for wet AMD and DME as well as 4D-175 for geographic atrophy."

16:09 EDT Digital Realty forms JV with GI Partners for stabilized hyperscale data centers - Digital Realty announced it has partnered with GI Partners to establish a joint venture for the sale of a 65% interest in two stabilized hyperscale data center buildings and their associated equipment in the Chicago metro area. Digital Realty will receive approximately $743M of gross proceeds related to the joint venture and the associated financing, and will maintain a 35% interest in the joint venture while continuing to manage the day-to-day operations of the assets, providing a seamless customer experience. Digital Realty has also granted GI Partners an option to purchase an interest in the third facility on the same hyperscale data center campus. Digital Realty originally acquired the facilities in 2017 through its merger with DuPont Fabros. The two data centers contributed to the joint venture contain approximately 67 megawatts of IT capacity and are 90% occupied in aggregate, primarily by investment grade customers. Based on annualized in-place cash NOI at June 30, 2023 and the benefit of leases signed but not yet commenced, the transaction values the two facilities at approximately a 6.5% cap rate. Net proceeds will be used to pay down debt and for general corporate purposes.

16:07 EDT Inhibikase Therapeutics regains Nasdaq compliance - Inhibikase Therapeutics announced that it received written notice on July 17, 2023 from the Listing Qualifications Staff of The Nasdaq Stock Market indicating that Inhibikase Therapeutics has regained full compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2), and that Inhibikase is in compliance with all applicable listing standards.

16:06 EDT Karyopharm receives FDA Track Designation for selinexor - Karyopharm Therapeutics announced that the United States Food and Drug Administration FDA has granted Fast Track Designation to the development program of selinexor for the treatment of patients with myelofibrosis, including primary myelofibrosis, post-essential thrombocythemia myelofibrosis, and post-polycythemia vera myelofibrosis.

16:05 EDT Wolfspeed says supply chain not impacted by China Ministry of Commerce decision - Wolfspeed issued the following statement regarding the recent decision by the Chinese Ministry of Commerce to restrict the export of gallium and germanium which is scheduled to take effect on August 1, 2023. The statement can be attributed to Wolfspeed spokesperson Melinda Walker. "Following an internal review, the company has confirmed that its supply chain will not be impacted by the proposed export restrictions on gallium and germanium. Wolfspeed strives to manage its supply chain with our supply partners through principles such as quality, availability, social responsibility, and cost. We appreciate that global events can lead to dynamic market conditions that will require us to periodically review our supply chain, and we will continue to do so to ensure Wolfspeed's needs are fulfilled."

14:51 EDT Apellis Pharmaceuticals trading resumes

14:29 EDT Salesforce announces Sabastian Niles as Chief Legal Officer - Salesforce announced that Sabastian Niles will join the company as President and Chief Legal Officer, overseeing Salesforce's global Legal and Government Affairs organizations. Sabastian will report to Chair and CEO Marc Benioff and serve on the company's executive leadership team. Sabastian joins Salesforce from Wachtell, Lipton, Rosen & Katz, where he has been a partner working with U.S. and overseas companies, the company noted. Reference Link

14:12 EDT Freedom Acquisition I Corp trading resumes

13:26 EDT Can-Fite granted abstract award for Namodenoson to treat HCC by ASCO - Can-Fite BioPharma announced its abstract titled "A novel approach for the treatment of advanced hepatocellular carcinoma or HCC is one of the highest scoring abstracts and has won the prestigious Breakthrough Abstract Award from Conquer Cancer, the ASCO Foundation, and the 2023 ASCO Breakthrough Program Committee. Can-Fite's Chief Scientific Officer, Founder, and Executive Chairman, Dr. Pnina Fishman, will present the poster at the ASCO Breakthrough Meeting which will take place August 3 - 5, 2023 in Yokohama, Japan. Namodenoson has received significant acknowledgment in the scientific and medical community, as evidenced by the numerous peer-reviewed publications and conferences in which it has been published and presented. Currently being evaluated in a pivotal Phase 3 multinational registration trial for the treatment of HCC and underlying Child Pugh B7, Namodenoson has also completely cleared cancer in an HCC patient who was enrolled in Can-Fite's Phase 2b HCC trial. The patient continues to be treated through a compassionate use program in Romania, where she remains cancer-free more than six years following her first dose of Namodenoson. "We are honored to receive this prestigious award from Conquer Cancer and ASCO," Dr. Fishman stated. "Our Phase 3 registration trial is designed to treat patients who have tried, yet not benefitted from the few other FDA-approved HCC treatments on the market today. We are hopeful that Namodenoson, with its liver-protective properties, can safely prolong life for advanced liver cancer patients."

13:06 EDT Sanofi, AstraZeneca confirm FDA approves Beyfortus for RSV disease in infants - The U.S. Food and Drug Administration has approved Sanofi (SNY) and AstraZeneca's (AZN) Beyfortus for the prevention of respiratory syncytial virus, or RSV, lower respiratory tract disease in newborns and infants born during or entering their first RSV season, and for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season, the companies confirmed. "The companies plan to make Beyfortus available in the U.S. ahead of the upcoming 2023-2024 RSV season. RSV is the leading cause of hospitalization for infants under the age of one in the U.S., averaging 16 times higher than the annual rate for influenza. Each year, an estimated 590,000 RSV disease cases in infants under one require medical care, including physician office, urgent care, emergency room visits and hospitalizations," the companies stated.

12:07 EDT 3D Systems expects Stratasys-Desktop Metal merger to be terminated - 3D Systems (DDD) said it "welcomed" the determination by the board of Stratasys (SSYS) that 3D Systems' proposal to combine with Stratasys is reasonably expected to result in a "superior proposal" under the terms of Stratasys' merger agreement with Desktop Metal (DM). On July 13, 3D Systems delivered a signed merger agreement in escrow to Stratasys that provides for the shareholders of Stratasys to receive $7.50 per share in cash and 1.5444 newly issued shares of common stock of the combined company for each Stratasys ordinary share. The combination would result in Stratasys shareholders owning approximately 44% of the combined company and receiving approximately $540M in cash at the time of consummation of the transaction. 3D Systems "expects Stratasys to swiftly agree with Desktop Metal to terminate the Desktop Metal-Stratasys merger agreement and countersign the 3D Systems-Stratasys merger agreement, which is already signed by 3D Systems and now sits in escrow. 3D Systems commits to pay the full amount of any termination fees due to Desktop Metal upon the termination of the Desktop Metal merger agreement and Stratasys' countersignature of the 3D Systems merger agreement."

12:00 EDT Farfetch falls -7.1% - Farfetch is down -7.1%, or -45c to $5.80.

12:00 EDT Yelp rises 11.3% - Yelp is up 11.3%, or $4.31 to $42.44.

12:00 EDT Black Knight rises 13.5% - Black Knight is up 13.5%, or $8.27 to $69.53.

11:53 EDT Sanofi, Scribe Therapeutics expand collaboration for in vivo genetic medicines - Scribe Therapeutics announced an expanded collaboration with Sanofi. Under the agreement, Sanofi receives an exclusive license to use Scribe's CRISPR X-Editing genome editing technologies for the development of in vivo therapies, including sickle cell disease. The agreement follows the launch of the companies' existing collaboration focused on ex vivo editing of natural killer cell therapies for the treatment of cancer. The in vivo collaboration will leverage Scribe's precisely engineered CRISPR XE technologies and Sanofi's capabilities in non-viral delivery to address an initial target for sickle cell disease. Scribe's proprietary CRISPR by Design approach powers the only platform that uses holistic engineering to transform bacterial immune systems into therapeutically relevant genome editing technologies. By combining Scribe's novel technologies with Sanofi's proven expertise in developing and manufacturing therapeutics on a global scale, the companies will seek to advance potentially breakthrough genomic medicines for the in vivo treatment of sickle cell and other diseases. Under the terms of the agreement, Scribe will receive $40M in upfront payment and is eligible to potentially receive more than $1.2B based on the successful completion of certain development and sales milestones. Scribe will also be eligible to receive tiered royalties that range from high single digits to low double digits on net future sales on any products that may result from this agreement. Scribe has a right to opt-in to development cost sharing, as well as co-promotion and profit and loss sharing in the U.S. on one future program.

10:43 EDT Nano Dimension receives HSR clearance for Stratasys special tender offer - Nano Dimension (NNDM) announced that the waiting period under the Department of Justice's Hart-Scott-Rodino Antitrust Improvements Act of 1976 has expired in connection with its special tender offer for Stratasys (SSYS); thus, no further regulatory review by U.S. antitrust authorities is required in connection with the special tender.

10:21 EDT Eli Lilly presents full results from Phase 3 TRAILBLAZER-ALZ 2 study - Eli Lilly and Company presented full results from the Phase 3 TRAILBLAZER-ALZ 2 study showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer's disease. The data were shared at the 2023 Alzheimer's Association International Conference as a featured symposium and simultaneously published in the Journal of the American Medical Association. Lilly previously announced that donanemab met the primary and all cognitive and functional secondary endpoints in the Phase 3 study. Submission to the U.S. FDA for traditional approval was completed last quarter with regulatory action expected by the end of the year. Submissions to other global regulators are currently underway, and the majority will be completed by year end. The TRAILBLAZER-ALZ 2 results support Lilly's application for regulatory approval to treat people with amyloid-positive early symptomatic Alzheimer's disease, regardless of their baseline level of tau. TRAILBLAZER-ALZ 2 enrolled participants with a broader range of cognitive scores and amyloid levels than other recent trials of amyloid plaque-targeting therapies. Participants in TRAILBLAZER-ALZ 2 were stratified by their level of tau, a predictive biomarker for disease progression, into either a low-medium tau group or a high tau group, which represented a later pathological stage of disease progression. All participants were then assessed over 18 months using scales that measure both cognition and function, including the integrated Alzheimer's Disease Rating Scale and the Clinical Dementia Rating-Sum of Boxes. As previously reported, among participants with low-medium levels of tau, donanemab treatment significantly slowed decline by 35% on iADRS and 36% on CDR-SB. Among all amyloid-positive early symptomatic AD study participants, treatment with donanemab significantly slowed decline by 22% on iADRS and 29% on CDR-SB. Additional data presented at AAIC reinforced that regardless of baseline clinical or pathological stage of disease, treatment with donanemab resulted in cognitive and functional benefits relative to placebo: A pre-specified subpopulation analysis of low-medium tau participants based on clinical stage showed greater benefit of donanemab in those at earlier stage of disease: In participants with mild cognitive impairment, donanemab slowed decline by 60% on iADRS and 46% on CDR-SB. Similarly, a post-hoc subgroup analysis of low-medium tau participants based on age showed greater benefit of donanemab in patients under the age of 75: In participants under the age of 75, donanemab slowed decline by 48% on iADRS and 45% on CDR-SB. In participants aged 75 or greater, donanemab slowed decline by 25% on iADRS and 29% on CDR-SB. Results were similar across other subgroups, including participants who carried or did not carry an ApoE4 allele. The overall treatment effect of donanemab continued to grow throughout the trial, with the largest differences versus placebo seen at 18 months. Donanemab specifically targets deposited amyloid plaque and has been shown to lead to plaque clearance in treated patients. Treatment with donanemab significantly reduced amyloid plaque levels regardless of baseline pathological stage of disease. Among all participants, treatment with donanemab reduced amyloid plaque on average by 84% at 18 months, compared with a 1% decrease for participants on placebo. Participants were able to stop taking donanemab once they achieved pre-defined criteria of amyloid plaque clearance. Approximately half of participants met this threshold at 12 months and approximately seven of every ten participants reached it at 18 months. In the earlier pathological stage of disease in participants with low-medium tau, treatment with donanemab resulted in 47% of participants with no progression at one year on the CDR-SB assessment, versus 29% on placebo. Those participants treated with donanemab also had a 39% lower risk of progressing to the next clinical stage of disease over the 18-month trial. This delay in progression meant that, on average, participants treated with donanemab had an additional 7.5 months before they reached the same level of cognitive and functional decline on CDR-SB compared to those on placebo. The incidence of amyloid-related imaging abnormalities and infusion-related reactions was consistent with the previous TRAILBLAZER-ALZ study. ARIA occurs across the class of amyloid plaque clearing antibody therapies. It is most commonly observed as temporary swelling in an area or areas of the brain or as microhemorrhages or superficial siderosis, in either case detected by MRI, and these may be serious and even fatal in some cases. This risk should be managed with careful observation, monitoring with MRIs, and appropriate actions if ARIA is detected. Serious infusion-related reactions and anaphylaxis were also observed.

10:10 EDT Nano Dimension urges Stratasys shareholders to replace board at AGM - Nano Dimension (NNDM), which owns approximately 14.1% of Stratasys' (SSYS) outstanding ordinary shares, encourages Stratasys Shareholders to replace their entrenched Board with Nano Dimension's director nominees through their upcoming vote at Stratasys' August 8th, 2023 Annual General Meeting. The company said, in part, "The Stratasys Board of Directors have checkered personal backgrounds as well as a warped command corporate governance. Nano is calling for a replacement of the Stratasys Board's members in order to re-align Stratasys' governance with the interest of shareholders. The new board will focus on enabling the present competing bids to increase shareholder value PREVENTING the present Board of Directors from blocking two alternatives for Stratasys' Shareholders...The actions of the current Stratasys Board of Directors have raised significant concerns about their practices and lack of commitment to shareholder interests: 6 of the 8 directors have spent an alarmingly long time together on the Board, suggesting a lack of new perspectives and fresh ideas, not to speak about obvious years of "one-hand-washes-the-other" issues. They have demonstrated a blatant disregard for shareholders' interests and resistance to change. Attempts to add a new independent director as recently as 2-3 years ago were met with pushback. While a new director joined the Board in 2020, he was ousted barely a year later in 2021 following some self-serving corporate governance maneuvers geared at maintaining the underperforming status quo and the mummified Board's grip on power. The Stratasys Board has lined their own pockets while overseeing poor performance, indulging themselves with exorbitant salaries and annual equity grants, cumulatively equaling approximately $1,820,0001 in FY 2022 for 8 directors, not including meeting fees, and travel & entertainment expense...IN CONTRAST, Nano's candidates to replace the Stratasys board are highly qualified with extensive experience overseeing value creation: Nano Dimension is recommending Stratasys shareholders replace its entrenched non-performing directors at Stratasys' Annual General Meeting to be held on August 8th, 2023, with professional executives who will devote a serious amount of their business time and attention to improve value for Stratasys shareholders. The seven members proposed by Nano include over 10 CEO roles, as well as four ex-founders of successful high-tech and multi-hundred million dollars companies, Chief Technology Officers, ex-CFOs/COOs and ex-members of KPMG and PWC. All their compensation for service as members of the Stratasys' Board will be based on the company's performance, not just on being present in meetings."

10:06 EDT Prestige Wealth Inc trading halted, volatility trading pause

10:05 EDT Anson, Cable Car file materials to remove entire Methode Pharma board - Earlier, Anson Funds and Cable Car Capital, which collectively beneficially own approximately 14.8% of the outstanding common stock of MEI Pharma, announced that they have filed preliminary consent materials with the Securities and Exchange Commission regarding their solicitation of written consents from stockholders in lieu of a stockholder meeting to remove the entire Board of Directors of MEIP and issued the following statement: "In our view, the current Board has not operated with stockholders in mind and needs to be held accountable. We believe the Board has repeatedly exhibited poor judgment and has failed to listen to stockholders, as evidenced by its decision to pursue a value-destructive and speculative transaction with Infinity Pharmaceuticals and its apparent refusal to accept that the transaction has seemingly failed to garner support from stockholders, the true owners of the Company. We are launching this consent solicitation because we believe immediate action must be taken to prevent the further destruction of value. Removing the current directors is an important first step in reconstituting the Board and creating meaningful change at the Company. The Board's unwillingness to return capital to stockholders and refusal to engage with us regarding our all-cash acquisition proposal, in our view, evinces its fundamental misunderstanding of its role as steward of stockholder resources. We believe the stockholders of MEIP deserve a well-functioning Board that understands its role and will prioritize the best interest of stockholders. We look forward to continuing to engage with our fellow stockholders over the coming weeks and invite you to review our preliminary consent statement, which explains further why we believe urgent change on the Board is needed."

10:02 EDT Callaway Golf, Jon Rahm announce long-term partnership extension - Callaway Golf and Jon Rahm announced a new long-term partnership extension. Rahm joined Callaway in 2021 and earned his first major championship win at the 2021 U.S. Open at Torrey Pines, which moved him to Number One in the World Golf Rankings. He won three more times in 2022 and has continued his remarkable run of form this season. Jon leads the PGA TOUR with four wins in 2023, highlighted by his second major championship in April at Augusta, where he delivered a masterful performance to secure the Green Jacket. Rahm will continue to play a full bag of Callaway and Odyssey equipment, wear Callaway headwear, TravisMathew apparel and footwear, and champion Topgolf's global golf entertainment venue business. This extension includes an equity position for Rahm in Topgolf Callaway Brands.

10:00 EDT Telephone and Data falls -5.1% - Telephone and Data is down -5.1%, or -39c to $7.25.

10:00 EDT Farfetch falls -6.2% - Farfetch is down -6.2%, or -39c to $5.86.

10:00 EDT Posco rises 7.7% - Posco is up 7.7%, or $6.62 to $93.12.

09:55 EDT Lixte Biotechnology Holdings Inc trading halted, volatility trading pause

09:47 EDT Twilio falls -5.1% - Twilio is down -5.1%, or -$3.43 to $63.46.

09:47 EDT Telephone and Data falls -6.8% - Telephone and Data is down -6.8%, or -52c to $7.12.

09:47 EDT Posco rises 7.8% - Posco is up 7.8%, or $6.79 to $93.29.

09:44 EDT Immix Biopharma second interim clinical trial data readout for IMX-110 - Immix Biopharma (IMMX) announced its 2nd IMX-110 interim update from the Company's ongoing Phase 1b/2a IMMINENT-01 study of IMX-110 in combination with BeiGene's (BGNE) anti-PD-1 antibody tislelizumab. As of the July 7, 2023 data cutoff date, out of 4 relapsed/refractory metastatic colorectal cancer patients treated with IMX-110 + tislelizumab: 3 out of 4 patients experienced tumor shrinkage at 2 months; 1 out of 4 patients experienced tumor control at 2 months; 1 out of 4 patients remain on IMX-110 + tislelizumab therapy as of July 7 2023; Median progression-free survival and overall survival not yet reached; Patients received a median of 8 earlier anti-cancer treatments that failed to halt cancer growth prior to receiving IMX-110 + tislelizumab and all 4 had proficient mismatch repair relapsed/refractory mCRC; IMMINENT-01 continues to enroll the next cohort of patients at a higher dose. Dosing of the second cohort of three relapsed/refractory cancer patients is complete, as of July 7, 2023, for the ongoing Phase 1b portion of the IMMINENT-01 Phase 1b/2a clinical trial investigating IMX-110 in combination with BeiGene anti-PD-1 antibody tislelizumab in relapsed/refractory solid tumors, including relapsed/refractory colorectal cancer. No dose limiting toxicities have been observed in the first 2 cohorts; the trial is now enrolling the next cohort of three patients at a higher dose of IMX-110 in combination with anti-PD-1 antibody tislelizumab. The efficacy evaluable population in IMMINENT-01 includes patients who have completed at least 1 follow-up RECIST assessment. Tumor growth is assessed every 2 months. To put this clinical trial update in perspective, multi-kinase inhibitor regorafenib combined with best supportive care in relapsed/refractory metastatic colorectal cancer patients with median 3 prior lines of therapy produced progression free survival of 2 months and a 1% response rate according to the FDA approval label. This study was not a head-to-head evaluation with IMX-110 and differences exist between trial designs, subject characteristics, and caution should be exercised when evaluating clinical data across studies.

09:31 EDT X-Energy selects Howden as preferred supplier of helium circulator system - Chart Industries announced that X-Energy Reactor Company has selected Chart as its preferred strategic supplier of its helium circulator system into its Xe-100 high temperature gas cooled advanced modular reactor for the United Kingdom market. Chart's Howden business, based in Glasgow, Scotland, has over 50 years of experience in the nuclear sector and provides several industry-proven products in a variety of reactor designs and provides custom-designed fans and compressors which are found at all the most critical points throughout the nuclear industry.

09:25 EDT MasterCard appoints Rob Beard as chief legal officer - Mastercard (MA) announced the appointment of Rob Beard as chief legal officer, general counsel and head of global policy. He will oversee the company's legal, public policy, regulatory affairs, and litigation teams around the world, reporting to Tim Murphy, Chief Administrative Officer. Rob has over 20 years of experience and joins Mastercard from Micron (MU), one of the world's largest semiconductor companies. He was the general counsel and corporate secretary, leading its global legal, intellectual property, and ethics and compliance functions, and guiding the company's growth through an increasingly complex geopolitical environment.

09:21 EDT American International Holdings receives funding commitment up to $20M - American International Holdings has entered into an Equity Financing Agreement with Pacific Lion pursuant to which Pacific Lion agreed to purchase up to $20,000,000 of AMIH common stock. Pacific Lion also agreed to fund AMIH up to $400,000 under a Convertible Promissory Note to bridge AMIH through to the effectiveness of the registration of the shares to be sold under the Equity Financing Agreement. Pursuant to the Equity Financing Agreement, Pacific Lion has agreed to purchase up to $20,000,000 of AMIH common stock following the receipt of put notices from AMIH and subject to certain conditions. Pursuant to the Registration Rights Agreement entered into in connection with the Equity Financing Agreement, AMIH agreed to file a registration statement to register the common stock issuable under the Equity Financing Agreement. Following the effectiveness of the registration statement, if AMIH elects to cause Pacific Lion to purchase shares, the shares will be purchased at a 15% discount to the lowest closing trade price of AMIH's common stock in the prior 10 trading days. The Equity Financing Agreement with Pacific Lion replaces the Equity Financing Agreement previously entered into with GHS Investments LLC, which has been terminated. Pursuant to the Convertible Promissory Note issued to Pacific Lion by AMIH, Pacific Lion has the right to fund up to $400,000. The note bears interest at 6% and is due on May 23, 2024. Following an uplisting to a senior stock exchange, the note will automatically convert at 80% of the uplisting offering price. In addition to the note, the Company also issued a Warrant to Purchase Shares of Common Stock to Pacific Lion. The warrant is exercisable for 500,000 shares for a period of five years at $0.10 per share. In the event that an uplisting to a senior stock exchange does not occur within nine months of the issuance date, the warrant will automatically be canceled. The note is designed to provide a mechanism for Pacific Lion to make regular fundings to cover AMIH's working capital needs during the pendency of the registration statement. Pacific Lion funded the first tranche of $100,000 upon the issuance of the note. The proceeds will be used for general business operations. These investments are part of a broader restructuring plan to recapitalize the company, consolidate and retire existing debt and reduce dilution. This restructuring is designed to drive shareholder value and strengthen the balance sheet of the company. In addition to the investment made by Pacific Lion in AMIH, the company will also be working with Pacific Lion, a firm that specializes in delivering strategic direct investments and hands-on advisory services to help with the growth of early-stage companies. Another funding strategy the company intends to employ is to file an offering under Regulation A+. Regulation A+ allows companies to raise money under two different tiers. Fully reporting SEC reporting companies such as AMIH are able to raise up to $75,000,000 on a Tier 2 offering in any 12-month period from the general public. The company hopes to attract a new shareholder base and would like to help fund the company directly.

09:19 EDT DOE selects JV led by Amentum with Fluor and Cavendish for $5.87B contract - Fluor Corporation announced that the U.S. Department of Energy DOE selected Southern Ohio Cleanup Company a joint venture led by Amentum with Fluor and Cavendish Nuclear USA, to execute the Portsmouth Gaseous Diffusion Plant Decontamination and Decommissioning Contract in Piketon, Ohio. The single award Master Indefinite-Delivery/Indefinite-Quantity contract under the End State Contracting Model has an estimated value of $5.87B, over a 10-year ordering period, and performance of task orders issued up to an additional five years. Fluor will book its initial annual portion of the contract in the third quarter of 2023..."Fluor and our partners have an unsurpassed performance record of delivering on important decontamination and decommissioning work across the Department of Energy complex," said Tom D'Agostino, president of Fluor's Mission Solutions business. "We have worked at the Portsmouth site and have been involved in the community for the past 12 years-we know the importance of staying local. We are proud that this contract includes local small business partners who are committed to building an environmentally and economically sustainable future for southern Ohio. We look forward to maintaining our momentum and working collaboratively with the DOE, regulators, stakeholders and the community."

09:15 EDT Novan trading resumes

09:10 EDT Ligand offers to acquire Novan for $15M in cash, $15M in financing - Ligand (LGND) announced that it has made an offer to acquire the assets of Novan (NOVN) for $15M in cash and provide up to $15M in DIP financing to Novan inclusive of a $3M bridge loan already funded. Novan announced earlier that it has filed for Chapter 11 reorganization and its entry into a stalking horse acquisition offer with Ligand. The transaction is designed to preserve and maximize the value of Novan's commercial business and berdazimer gel development assets. Berdazimer gel is in development for molluscum contagiosum infection, which has a filed new drug application with the FDA with an assigned PDUFA goal date of January 5, 2024. Ligand acquired milestone and royalty rights to berdazimer gel in 2019. If Ligand's bid is the successful bid in the anticipated bankruptcy sale and auction process, Ligand will acquire the Novan assets and consistent with Ligand's business model, will seek to out license or sell the existing development programs and commercial business assets of Novan. The terms of the proposed transaction are outlined below: Ligand has submitted a $15 million bid to acquire all the assets of Novan, including berdazimer gel, all other programs in development, the NITRICIL drug delivery technology, and the commercial assets of its EPI health business. Subject to court approval, Novan will be able to draw down from the $15M secured DIP loan during the bankruptcy cases and will be repaid through the sale of Novan's assets. The $15M DIP loan will accrue interest at 12% interest annually and will be subject to a 6% increase in interest should Novan default on its loan agreement. Should the court accept a bid for the assets of Novan from another party, Ligand's DIP loan will be repaid, and Ligand expects that its milestone and royalty rights will be preserved. The transaction is expected to close in the third quarter of 2023.

09:10 EDT InterDigital received cash payment of $184.9M in case against Lenovo - In a regulatory filing, InterDigital (IDCC) disclosed that on July 11 the company received a cash payment in the amount of $184.9M related to its UK High Court case against Lenovo (LNVGY) equal to the amount the court ordered Lenovo to pay for a license through 2023. "At this time the company expects to defer recognizing any additional catch-up revenue until the appeal process progresses," the filing stated.

09:09 EDT Bright Green announces plan to support universities for cannabis research - Bright Green announced that it is launching a university based EB-5 initiative to provide foreign students attending universities in the United States the opportunity to purchase an EB-5 visa through Bright Green. Given that the U.S. has the largest number of top universities in the world, it is one of the most preferred destinations for foreign students to pursue their studies. Seamus McAuley, Bright Green's Chief Executive Officer, commented: "We are very excited to announce our plan to support U.S. university cannabis research and our foreign student EB-5 initiative, both of which touch on two very important strategic goals for the Company. First, raising capital to execute on our plans for the business, a primary focus for the Company moving forward. Second, we are also very excited to establish strong working relationships with the centers for higher learning across the United States given our absolute dedication to the application of scientific rigor to the development of our medicines and therapies. We firmly believe that the cannabis industry must be led by the scientific and research professionals who aim to harness cannabis's therapeutic benefits in a safe, compliant, consistent, and targeted way... Our goal is to support each institution according to their needs and preference so that they can maximize their engagement in our program. As the Bright Green business develops and unfolds, we will increasingly require skilled and qualified individuals, across a number of disciplines, to join or work with our team to help drive the development, research, and ultimately manufacturing of our medicines and medical therapies where we will develop further commercialization.'

09:07 EDT First Bank completes its acquisition of Malvern Bancorp - First Bank (FRBA) announced that its acquisition of Malvern Bancorp (MLVF) was completed before the open of business on July 17, 2023. The combined stock and cash transaction was valued at approximately $129.7 million and will expand First Bank's footprint in the highly desirable New York City to Philadelphia corridor. The consolidated assets of the combined company equal approximately $3.8 billion. "We are pleased to welcome Malvern customers, employees and shareholders to First Bank as we grow our banking presence in New Jersey and Pennsylvania," said Patrick Ryan, President and Chief Executive Officer of First Bank. "Malvern Bank has built a strong customer base by providing extraordinary customer service and we intend to continue this tradition." Effective upon the closing of the merger, First Bank expanded its Board of Directors by three seats and appointed three Malvern directors, Andrew Fish, Howard Kent and Cynthia Felzer Leitzell, to the First Bank Board.

09:05 EDT Blue Water Biotech issues letter to shareholders from CEO Hernandez - Blue Water Biotech issued the following letter to shareholders from its Chairman and Chief Executive Officer, Joseph Hernandez. "In recent months, Blue Water Biotech has evolved from a preclinical vaccine development company to a commercial stage pharmaceutical company after the purchase of several FDA approved assets spanning multiple treatment areas... Our recent acquisitions include ENTADFI, an FDA approved, once daily pill combining finasteride and tadalafil for the treatment of benign prostatic hyperplasia, and six additional FDA approved assets across multiple indications... In February 2023, we appointed Frank Jaeger to the team as Senior Vice President of Marketing and Business Development, bringing with him over 25 years of biopharmaceutical experience from start-up to large global pharma and targeted launch experience in Men's Health... With our commercial leadership team in place, we have identified key areas on which to focus our efforts, including expanding product availability for our patients, as well as marketing and advertising to increase awareness for our products through multiple channels. We have taken key steps to ensure that patients have proper access to therapy, including securing a license from the Ohio State Board of Pharmacy, allowing us to operate as a pharmaceutical wholesaler in our home state of Ohio... In addition to the traditional retail pharmacy channel, our commercial team has identified telemedicine as a potential solution for select patients to access therapy without having to step into a healthcare provider's office... In order to help patients access our products, we plan to partner with a hub provider to not only address the challenges that patients may have during the treatment journey, but also to help ease the administrative burden on healthcare providers... Regardless of the channel our patients utilize to access our therapies, our commercial team recognizes that payer coverage and market access is critical to the success of any pharmaceutical launch. To this end, we recently signed an agreement with Advantage Point Solutions, LLC to support our market access strategy and to assist in formulary negotiations with key healthcare payers and pharmacy benefit managers for ENTADFI... To summarize, the last few months have certainly been an exciting time for Blue Water, filled with acquisitions, growth, and execution. Although we have made significant progress on our launch plans in a short period of time, we also look forward to achieving the key milestones outlined above and generating additional value for our shareholders."

09:04 EDT CarGurus appoints Manik Gupta to board of directors - CarGurus (CARG) announced the appointment of Manik Gupta to its Board of Directors and Audit Committee, effective July 14, 2023. Gupta brings nearly 25 years of experience in the technology sector, currently as the Corporate Vice President of Microsoft Teams (MSFT).

09:02 EDT Flushing Financial announces acquisition of former Signature Bank team - Flushing Financial Corporation (FFIC) announced that it has acquired a commercial real estate lending team from the former Signature Bank (SBNY). John R. Buran President and CEO, stated, "The recent market disruptions have presented an opportunity to acquire talent from competitors negatively impacted by the banking crisis. We are particularly pleased to bring this team on board at a time when, despite continuing rate-related head winds, our loan pipeline continues to grow."

09:00 EDT Calavo Growers rallies after CEO buys $2.275M of shares - Shares of Calavo Growers are moving higher after its CEO Lecil Cole disclosed late Friday to purchase of 75,000 for an average price of $30.34. Cole spent $2.275.5M buying the stock and now owns 515,000 shares of Calavo Growers. The stock in premarket trading is up 3% to $31.80.

08:51 EDT Ford to increase plant capacity in effort to lower F-150 Lightning MSRP - Ford is taking advantage of increased plant capacity, continued work on scaling production and cost, and improving battery raw material costs to help lower the MSRP of F-150 Lightning for all customers. The Rouge Electric Vehicle Center in Michigan is temporarily closed to complete final plant upgrades to triple the plant's annual run rate to a targeted 150,000 F-150 Lightning trucks beginning this fall. The upgrades at the plant, combined with improving battery raw material costs and continued work on scaling production and cost, help make it possible to lower pricing across the F-150 Lightning line. Customers will now have greater availability of their built-to-order truck as early as October at an MSRP closer to initial Lightning pricing.

08:50 EDT Neuronetics receives regulatory clearance in South Korea for NeuroStar TMS - Neuronetics announced that the Ministry of Food and Drug Safety in South Korea has authorized multiple features of NeuroStar TMS for sale and distribution in the country - including an expansion of the indication to now include patients with major depressive disorder that exhibit comorbid anxiety symptoms, the NeuroStar 3.7 platform, MT Cap, and D-Tect MT Accessory. This marks the first international market where NeuroStar has obtained marketing authorization for the expanded indication and cutting-edge technologies.

08:43 EDT Greenlane launches Cara+ portable concentrate device - Greenlane Holdings announced the launch of the Cara+ portable concentrate device by house brand Groove. Greenlane launched the Groove brand in Fall 2022 to offer simple, functional, and reliable products at an affordable price point. The newest product, CARA+, delivers a high-quality solid concentrate device at a value price and further expands Groove's product offerings that include glass, vaporizers and accessories.

08:41 EDT Marriott, MGM Resorts announce long-term license agreement - Marriott International (MAR) and MGM Resorts International (MGM) announced an exclusive long-term strategic licensing agreement and the creation of MGM Collection with Marriott Bonvoy, which will launch in October 2023, and encompass 17 of MGM's unrivaled resorts, representing more than 40,000 rooms in Las Vegas and other cities across the U.S. Beginning in October, several MGM Collection with Marriott Bonvoy resorts will be available for booking on Marriott's robust digital platforms, including Marriott.com and the Marriott Bonvoy mobile app, with all properties expected to be available by the end of the year. These resorts will continue to be available on MGM Resorts' channels, including MGMRewards.com and the MGM Resorts mobile app. The agreement between MGM Resorts and Marriott will also benefit members of both companies' loyalty programs. Members of MGM Rewards, MGM Resorts' acclaimed loyalty platform with more than 40 million members globally, will be eligible to link accounts with Marriott Bonvoy and receive select member benefits. Members of Marriott Bonvoy, Marriott's award-winning loyalty platform with over 180M members globally, will be able to earn and redeem points for stays at all MGM Collection with Marriott Bonvoy properties.

08:40 EDT Republic, Castle Creek, Cohen Private Ventures terminate capital raise - Republic announced that it, affiliates of Castle Creek Capital and an affiliate of Cohen Private Ventures have mutually decided to terminate the previously announced agreement to raise $125M in capital for the Company through a private placement of equity securities. The Capital Raise was predicated on identifying additional investors to participate at the same $2.25 price per share as Castle Creek and Cohen Private Ventures by September 9, 2023. Given current market conditions - especially the widespread tightening of access to the equity capital markets across the banking sector - the parties do not believe that participants could be found on those terms by September 9th.

08:36 EDT Safe & Green: SG Echo expects to generate $130M of inter-company revenue - Safe & Green Holdings provided an update on its previously announced Magnolia Residential project...The Company reports that its 800 residential unit project is now in the architectural and engineering design phase. In parallel, the Company is advancing a variety of funding options, including prospective development partnerships at the project level, as well as non-dilutive funding options. The Company also reiterated that SG Echo expects to generate $130M of inter-company revenue from the project, while SG DevCo expects to benefit from a substantial increase in its asset base and future cash flow as a result of the development project...Paul Galvin, Chairman and CEO stated, "I am pleased to report SG DevCo is rapidly advancing the Magnolia Residential project and we are now developing the detailed site plan. We have received significant interest from potential limited partners to join us in this project, which we believe is further validation of the economic potential of this project and strong residential demand in the local market. Moreover, we are exploring a variety of non-dilutive funding options that would allow us to leverage the real estate and projected appraisal value of the project on completion."

08:36 EDT CSL Seqirus begins shipping portfolio of flu vaccines for 2023/24 U.S. season - CSL Seqirus, a business of CSL, announced it has begun to ship its portfolio of innovative cell-based, adjuvanted and egg-based influenza vaccines across the U.S. in preparation for the 2023/24 influenza season. The company is positioned to supply over 55M doses of influenza vaccines to healthcare providers across the U.S.

08:35 EDT Constellation's Perseus Group to acquire Black Knight's Optimal Blue for $700M - Constellation Software (CNSWF) announced that its Perseus operating group has entered into a binding commitment with Intercontinental Exchange (ICE) and Black Knight (BKI) to acquire Black Knight's Optimal Blue business. Under terms of the agreement, Constellation will acquire Black Knight's Optimal Blue business for $700M. The structure of the proposed transaction includes a payment by Constellation of $200M in cash, with the remainder financed by a $500M promissory note issued by Constellation to Black Knight, as a subsidiary of ICE, at the closing of the transaction. Completion of this transaction is subject to the closing of ICE's acquisition of Black Knight, the closing of Constellation's acquisition of Black Knight's Empower loan origination system business entered into earlier this year in March, and other customary closing conditions.

08:35 EDT Beckman Coulter Diagnostics, Fujirebio announce new partnership - Beckman Coulter Diagnostics and Fujirebio announced a new partnership combining their respective immunoassay strengths to support therapeutic development, clinical trials, reimbursement, and routine clinical adoption in the field of neurodegenerative diseases. The intersection of the growing prevalence of neurodegenerative disease and advances in disease-modifying therapies for Alzheimer's Disease makes the new Beckman Coulter and Fujirebio partnership evermore critical. This joint effort relies on Fujirebio's expertise in developing its first-to-market, high-quality neurodegenerative disease biomarker assays and generating the clinical evidence to drive clinical adoption. Beckman Coulter brings proprietary high-sensitivity detection capabilities and a broad installed base of immunoassay analyzers to drive global availability and support for development of more accurate next-generation solutions. To complement the current diagnostic solutions, which rely on PET-imaging or a lumbar puncture for cerebral spinal fluid testing, Fujirebio and Beckman Coulter intend to bolster widespread access to patient-friendly, blood-based diagnostic capabilities which will complement and accelerate the impact of breakthrough Alzheimer's Disease therapeutics.

08:32 EDT Imax announces $25M debut for 'Mission: Impossible- Dead Reckoning Part One' - Imax delivered its best global opening ever for Tom Cruise's venerated "Mission: Impossible" franchise with a $25M worldwide debut for "Mission: Impossible - Dead Reckoning Part One." Continuing its commanding market share of the summer box office, IMAX captured 10.6% of the film's worldwide debut on a fraction of overall screens. "Mission: Impossible - Dead Reckoning Part One" opened on 1505 Imex screens globally and notched the second highest grossing opening weekend in Imax of 2023. In North America, Imax delivered an impressive 14% of the Domestic box office with $11M, earning its highest share of opening weekend box office for any Domestic release this year. Imax has now scored double-digit market share for five consecutive Domestic debuts for the first time since 2018.

08:31 EDT Lixte announces results of collab with Netherlands Cancer Institute - LIXTE Biotechnology announced that a recently posted article in BioRxiv based on the results of a collaboration between the Company and the Netherlands Cancer Institute, shows that inhibition of PP2A in colon cancer cells, using LIXTE's lead clinical compound LB-100, leads to major changes in the way cancer cells process their mRNAs. Based on this finding, cancer cells are predicted to produce a significant number of aberrant proteins that can be recognized by the immune system. This newly discovered mechanism, by which LB-100 turns immunologically "cold" tumors "hot," adds to several additional mechanisms that have recently been described through which LB-100 sensitizes cancer cells to immune checkpoint blockade. John Kovach, M.D., CEO and Founder of LIXTE, said, "The case for combining LB-100 with immunotherapy is based on extensive pre-clinical data. The new findings provide a clear mechanistic underpinning for why this synergy is being seen. This data further supports our focus on developing LB-100 in combination with checkpoint blockade antibodies and strengthens our expectation that our current and upcoming clinical trials combining LB-100 with immune checkpoint blockade will be effective in treating cancer."

08:21 EDT Osisko Metals closes acquisition of Gaspe Copper project - Osisko Metals has completed the acquisition of a 100% interest in the past-producing Gaspe Copper Mine pursuant to a purchase agreement dated July 8, 2022 between the Company and Glencore Canada Corporation, a wholly-owned subsidiary of Glencore. In connection with the Transaction: Glencore was issued a $25M senior secured convertible note of the Company which is convertible into units of Osisko Metals at a price of $0.40 per unit, comprised of one common share of the Company and one-half Common Share purchase warrant of the Company. Each Warrant will be exercisable by Glencore at an exercise price of $0.46 per Common Share until July 14, 2026.The Convertible Note will bear interest at a rate equal to the Secured Overnight Financing Rate + 4%, payable annually and, subject to adjustment or acceleration in certain circumstances, all outstanding principal and interest under the Convertible Note will be repaid in full by July 14, 2026. The Convertible Note will be secured against all of the present and after acquired property of the Company. Upon full conversion of the Convertible Note and exercise of the underlying Warrants in full, Glencore would acquire 71,347,826 Common Shares, representing approximately 21.8% of the Common Shares that would be issued and outstanding upon the conversion of the Convertible Note and the exercise of the Warrants issued upon such conversion. Glencore did not own or control, directly or indirectly, any securities of Osisko Metals immediately prior to the closing of the Transaction. Glencore retained a 1% net smelter returns royalty on the historical Mount Copper open pit and a 3% NSR royalty on all other minerals extracted from Gaspe Copper. Osisko Metals will make a cash payment of $20M to Glencore upon the commencement of commercial production at Gaspe Copper. Osisko Metals is required to incur a total of C$55M in exploration, development and environmental expenditures, including permitting expenditures, over a period of four years, which commenced on March 25, 2022, with a minimum of C$20M to be incurred by March 25, 2024. Osisko Metals has entered into an offtake agreement with Glencore to purchase 100% of the concentrates produced at Gaspe Copper. The Company and Glencore entered into an investor rights agreement, pursuant to which Glencore has been granted certain investor rights, provided that it maintains certain ownership thresholds in the Company. Among other things, the Investor Rights Agreement provides Glencore with the right to designate one director for appointment to the board of directors of the Company, participation rights in future equity issuances, piggyback registration rights and the right to maintain its pro-rata position in Osisko Metals. Upon conversion of the Convertible Note by Glencore, Glencore may hold, on a post-conversion basis, such number of Common Shares and Warrants that would exceed 20% of the pro forma issued and outstanding Common Shares, both on a non-diluted and partially-diluted, post-conversion basis, thus resulting in Glencore becoming a Control Person of the Company. Accordingly, in accordance with the policies of the Exchange, the disinterested shareholders of the Company were required to approve Glencore as a Control Person of the Company, which approval was obtained at a meeting of shareholders held on June 23, 2022. In accordance with the terms of the Investor Rights Agreement, Mr. Peter Wright will be appointed to the board of the Company. Mr. Wright has served as Director and Vice President, Legal, with Glencore since 2018, having joined the company in 2014.

08:17 EDT Enveric: PK animal studies demonstrate 'more favorable' side effect profile - Enveric Biosciences announced positive results from PK animal studies demonstrating oral bioavailability, rapid onset of action and systemic clearance, and a more favorable side effect profile for the company's lead product candidate, EB-373. Pharmacokinetic PK measurements that were consistent in both dogs and rats confirmed that oral administration of EB-373, a psilocin-prodrug targeting anxiety disorders, resulted in dose-dependent increase in psilocin blood concentration, correlating to levels expected to be effective in humans. EB-373 demonstrated a very rapid conversion from prodrug to active metabolite psilocin, with concentrations of EB-373 that were approximately 100-fold lower in blood than psilocin and reached undetectable level after two hours. Additionally, psilocin blood concentration peaked at one hour after administration of EB-373 consistent with quicker onset of clinical effect. The side effect profile was well tolerated overall, with notably no vomiting and no serious adverse events observed at any dose level. ..Dr. Tucker added, "EB-373 treated animals exhibited reduced overall side effects, including GI upset and vomiting, compared to data from psilocybin reported in the literature. GI upset, vomiting, and the timing of both onset and resolution of effect are key target effects that EB-373 was designed to address leveraging our leading PsyAI machine-learning technology." Enveric intends to present thorough analyses of the PK animal studies for EB-373 at a future scientific conference.

08:14 EDT Ryvyl announces Simon & Edward as auditor of coyni - RYVYL announces Simon & Edward, LLP has been engaged as the accounting firm and auditor of coyni, Inc., replacing MaloneBailey effective July 12, 2023.

08:14 EDT Maris-Tech regains compliance with Nasdaq minimum closing bid price rule - Maris-Tech announced that it has received a written notice from The Nasdaq Stock Market that the Company has regained compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities, including the Company's ordinary shares, to maintain a minimum bid price of $1.00 per share. The Nasdaq staff made this determination of compliance after the closing bid price of the Company's ordinary shares was at $1.00 per share or greater for the 16 consecutive business days prior to the date of the notice. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), and Nasdaq considers the prior bid price deficiency matter now closed.

08:13 EDT Avertix Medical appoints Meredith to board of directors - Avertix Medical announced today that Professor Ian Meredith AM, has agreed to join the Company's Board of Directors following the closing of the Company's previously announced business combination with BIOS Acquisition Corporation (BIOS). Professor Meredith recently retired from Boston Scientific (BSX) after serving over six years as its Executive Vice President and Global Chief Medical Officer, where he was responsible for global leadership of medical, clinical science and trial strategy across the organization.

08:12 EDT Whole Earth Brands appoints Ohri, Robinson as interim co-CEOs - Whole Earth Brands announced that the Board of Directors of the Company has implemented an executive transition in connection with its Special Committee's review of the previously announced non-binding proposal received from Sababa Holdings FREE and the Board's broader consideration of potential strategic alternatives. On July 16, 2023, the Board unanimously resolved to place Michael Franklin, Chief Executive Officer of the Company, on a leave of absence, effective immediately. The Board determined that such action was required so the Board may adequately discharge its fiduciary duties in connection with the evaluation of the previously announced, non-binding proposal received by the Company from Sababa on June 25, 2023, as well as other strategic alternatives that may be available to the Company including maintaining the status quo as a standalone publicly-traded company. In the interim, the Board has appointed Rajnish Ohri, the Company's current President & Chief Operating Officer - International Business, and Jeffrey Robinson, the Company's current President Mafco, to act as the Company's Interim Co-Chief Executive Officers, effective July 16, 2023.

08:10 EDT PDS Biotechnology announces acceptance of abstract on PDS0301 with docetaxel - PDS Biotechnology Corporation announced that an abstract reporting on interim data from a first-in-human clinical trial evaluating the combination of PDS0301, an IL-12-based immunocytokine, with the chemotherapy medication docetaxel has been accepted for oral presentation at the 11th Annual Meeting of the International Cytokine & Interferon Society. The abstract, titled, "Combining an IL-12-based Immunocytokine with Docetaxel in Metastatic Prostate Cancer: Preliminary Safety and Immune Data", will report interim safety and immune data on 18 patients in the clinical trial being led by the National Cancer Institute, part of the National Institutes of Health. The trial is investigating the safety, immune responses and clinical activity of PDS0301 and docetaxel in metastatic castration-sensitive and castration-resistant prostate cancer patients. The study is designed to evaluate three dose levels of PDS0301 in combination with docetaxel administered every three weeks. "We look forward to Dr. Ravi Madan's presentation of the interim safety, clinical outcomes and immune correlates for PDS0301 administered in combination with standard of care docetaxel in patients with advanced prostate cancer," stated Dr. Lauren V. Wood, Chief Medical Officer of PDS Biotech. "This clinical trial provides an important opportunity to investigate the potential of PDS0301 combined with docetaxel chemotherapy to offer improved treatment options for patients with metastatic castration-sensitive and castration-resistant forms of prostate cancer. The results of this study could provide insight into the potential use of PDS0301 with chemotherapy across multiple solid tumors."

08:09 EDT MEI Pharma encourages shareholders to vote for Infinity transaction - MEI Pharma (MEIP) mailed the following letter to shareholders, encouraging them to vote FOR the pending transaction with Infinity Pharmaceuticals (INFI) in connection with the Company's special meeting on July 23 at 10:00 a.m. Eastern Time.

08:09 EDT Vaxxinity announces new Phase 1 trial data for UB-312 - Vaxxinity announced new data from a Phase 1 clinical trial demonstrating that antibodies derived from its investigational immunotherapeutic for Parkinson's disease, PD, UB-312, slows seeding of alpha-synuclein in cerebrospinal fluid, CSF, of patients with PD as demonstrated using multiple target engagement assays. These data signify that UB-312 has established clear target engagement in PD patient CSF, and provides further validation of Vaxxinity's platform technology in neurodegenerative disease. UB-312 is designed to target aggregated forms of aSyn, the toxic species that underlies Parkinson's disease and other synucleinopathies. Last month, Vaxxinity announced clinical data from Part B of its Phase 1 clinical trial of UB-312 demonstrating that UB-312 was well-tolerated and induced anti-aSyn antibody responses in participants with early PD, and that antibodies were detectable in the CSF. As part of this trial, The Michael J. Fox Foundation funded a 2-year collaborative project between Vaxxinity, the Mayo Clinic, and UTHealth Houston to analyze CSF collected from patients, and to conduct exploratory research to characterize the anti-aSyn antibodies produced after UB-312 administration and assess target engagement. Analyses from this and related research yielded insights about the pharmacodynamic effects of anti-aSyn antibodies generated by UB-312 in the Phase 1 trial: UB-312-derived antibodies show preferential binding to aggregated aSyn isolated from patients with PD and Multiple System Atrophy, as measured by dot blot; UB-312-derived antibodies successfully demonstrate inhibition of aggregation of aSyn in both a seed amplification assay and a protein misfolding cyclic amplification assay. These techniques can potentially be used to identify people with PD, and also to measure the treatment response and pharmacodynamic properties of UB-312-derived antibodies from subjects in clinical trials; Importantly, aSyn aggregation was slowed down in CSF samples from PD patients who received UB-312, as compared to those who received placebo, in the Phase 1 trial.

08:08 EDT Sangamo enters research evaluation, option agreement with Prevail - Sangamo (SGMO) announced it has signed an evaluation and option agreement with Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly (LLY), through which Prevail has been granted rights to evaluate certain proprietary adeno-associated virus, or AAV, capsids developed by Sangamo and may exercise certain options to license these capsids for multiple undisclosed neurological targets. Generated through Sangamo's AAV capsid engineering platform, SIFTER, these capsids have demonstrated a potential for high efficiency delivery of investigatory gene therapy constructs to the central nervous system in pre-clinical animal models following administration into the cerebrospinal fluid and seek to optimize delivery of therapeutics to a range of previously inaccessible areas. Under the terms of the global agreement, Prevail will evaluate Sangamo's proprietary capsids by performing in vitro and in vivo studies, with an option to obtain an exclusive license to use the capsids for certain neurological targets. Sangamo will provide the capsids to Prevail for evaluation in exchange for an upfront payment. If Prevail exercises its option for all targets, and a Prevail product is approved in the U.S. and Europe for each target, Sangamo would be eligible to receive exercise fees and developmental milestones of up to approximately $415 and commercial milestones of up to approximately $775M, in addition to tiered royalties based on net sales of Prevail products incorporating the licensed capsids. Prevail would lead all further development, manufacturing and commercialization of products incorporating the licensed capsids.

08:07 EDT Genpact expands partnership with o9 Solutions - Genpact announced it is expanding its partnership with o9 Solutions, an enterprise artificial intelligence software platform provider for transforming planning and decision-making, to help companies navigate ongoing supply chain disruptions by leveraging generative AI. Genpact's partnership with o9 solutions has expanded to cover a jointly developed leading-edge planning-as-a-service offering. This solution combines Genpact's expertise in digital innovation, process, supply chain transformation, and extensive experience running digital operations for hundreds of global retail, consumer goods, and manufacturing clients with o9's state-of-the-art technologies in generative AI, machine learning, and other digital intelligence capabilities.

08:06 EDT Corsair to acquire certain assets from peripheral developer Drop, no terms - Corsair Gaming announced that it has reached an agreement to acquire certain assets from Drop, a privately held peripheral developer best known for its customizable mechanical keyboards and switches, and its millions-member strong enthusiast community. Financial terms of the non-material, all-cash transactions were not disclosed. Founded in 2011, Drop develops and sells a portfolio of peripherals and enthusiast products, with the majority of its business coming from customized "DIY" keyboards, aftermarket designer keycaps and desktop accessories. Drop leveraged the insights of its members to develop its current collection of over 120 colorful, classic, and iconic sets offering an incredible degree of personalization to mechanical keyboard users from all walks of life. It recently expanded its portfolio to include a range of so-called Battlestation products to offer an even wider assortment of designer products for the desk and workspace...Drop will remain a separate brand within CORSAIR and all existing warranties, purchases and customer support requests will continue to be handled directly by the team at Drop.

08:05 EDT Madrigal Pharmaceuticals completes submission of NDA to U.S. FDA for resmetirom - Madrigal Pharmaceuticals announced the completion of the rolling submission of its New Drug Application, NDA, to the U.S. Food and Drug Administration, FDA, for resmetirom for the treatment of adults with NASH with liver fibrosis, a disease with no approved therapy. Madrigal has requested a priority review of the resmetirom NDA. Resmetirom is a once daily, oral, thyroid hormone receptor-beta selective agonist designed to target key underlying causes of NASH in the liver. The clinical development program for resmetirom is comprised of 18 clinical studies supporting the NDA: twelve Phase 1 studies, two Phase 2 studies, and four Phase 3 studies. Becky Taub, M.D., Chief Medical Officer and President of Research & Development of Madrigal, stated, "Based on the positive efficacy results observed in MAESTRO-NASH and the large safety database we have established across the MAESTRO trials, we believe resmetirom has the potential to become the first approved treatment for patients with NASH with liver fibrosis, a disease that is rapidly becoming the leading cause of liver transplantation in the U.S. Madrigal has generated a robust evidence package to support the FDA's benefit-risk evaluation and our two ongoing Phase 3 outcomes studies, one of which is already fully enrolled, reflect our commitment to verifying clinical benefit following a potential accelerated approval."

08:04 EDT Pathstone Family Office to acquire Veritable for $294M - Affiliated Managers Group entered into an agreement with Pathstone Family Office and Veritable, under which Pathstone will acquire 100% of the outstanding equity interests in Veritable. AMG will receive all of its transaction proceeds in cash at closing. AMG expects to use the gross cash proceeds of approximately $294M from the transaction to repay debt, fund future growth initiatives, and repurchase shares. As of May 31, 2023, Veritable managed approximately $17B in client assets. The transaction is expected to close in the second half of 2023, subject to customary closing conditions.

08:03 EDT Arcutis announces ZORYVE included in preferred position for CVS Caremark - Arcutis Biotherapeutics (ARQT) announced that ZORYVE cream 0.3% for the treatment of plaque psoriasis, including intertriginous psoriasis in adults and adolescents, is now covered as a preferred tier product on CVS (CVS) Caremark's largest national commercial formularies effective July 5. These national formularies provide access to an additional 20 million commercial lives in the United States. "This is the largest U.S. pharmacy benefit manager, and the third to include ZORYVE on its national formularies since we launched less than a year ago. We have now unlocked broad high-quality access for a total of 131 million commercially insured patients, representing 80% of covered lives in the United States. Notably, in line with our access goals, more than 90% of the 130 million covered commercial patients have access to ZORYVE without a prior authorization," said Frank Watanabe, President and CEO of Arcutis. "The placement of ZORYVE in a preferred tier position aligns with our focus on ensuring affordable access to ZORYVE so that adults and adolescents with plaque psoriasis can benefit from our effective and well-tolerated therapy."

08:02 EDT Pathstone to acquire Veritable from Affiliated Managers, terms not disclosed - Pathstone announced it is joining forces with one of the first and largest multi-family offices in the U.S., Veritable LP. Pathstone is acquiring Veritable from its management partners and Affiliated Managers Group. Upon completion of the deal, Pathstone's Assets Under Advisement and Administration will exceed $100B, with Pathstone providing services to an additional 200 clients who average over $75M in assets.

07:37 EDT Camping World promotes Lindsey Christen to Chief Administrative & Legal Officer - Camping World Holdings announced the promotion of Lindsey Christen to Chief Administrative and Legal Officer of Camping World Holdings, Inc. strengthening both its strategic and compliance functions to support continued growth. "Lindsey plays a vital role in the management and growth of Camping World, with great vision for the Company's future," said Marcus Lemonis, Chairman and Chief Executive Officer. "Over the past 15 years, Lindsey has gained deep industry knowledge and proven to be an effective leader, strategic thinker, and trusted partner. I believe her abilities will be invaluable as the Company continues to grow and evolve as an organization."

07:32 EDT Avicanna subsidiary SMGH exports CBD, CBG into Paraguay - Avicanna announces that through its majority owned subsidiary Santa Marta Golden Hemp, SMGH, the Company has completed the commercial export of aureus branded products into Paraguay. The commercial export included Aureus branded purified Cannabidiol, CBD, and Cannabigerol, CBG, which is a part of the company's portfolio of cannabinoid active pharmaceutical ingredients. This transaction also marks the 17th international market for Aureus branded products and 20th market for all Avicanna products which further demonstrates the company's capabilities in navigating complex regulatory processes for its commercialization efforts internationally.

07:32 EDT Arrowhead files application for clearance to initiate ARO-DUX4 trial - Arrowhead announced that it has filed an application for clearance to initiate a Phase 1/2 clinical trial of ARO-DUX4, the company's investigational RNA interference, or RNAi, therapeutic being developed as a potential treatment for patients with facioscapulohumeral muscular dystrophy, or FSHD. ARO-DUX4 is the first clinical candidate utilizing Arrowhead's proprietary Targeted RNAi Molecule platform to target disease associated genes in skeletal muscle.

07:16 EDT Fisker to produce 100 Fisker Extreme Vigyan Edition SUVs for India market - Fisker will produce 100 Fisker Extreme Vigyan Edition all-electric SUVs for the India market.

07:15 EDT Clearside Biomedical announces enrollment, dosing of participants in ODYSSEY - Clearside Biomedical, announced that the enrollment and dosing of participants is underway in ODYSSEY, its randomized, Phase 2b clinical trial of CLS-AX in neovascular age-related macular degeneration. "The ODYSSEY clinical trial is off to a solid start with the activation of multiple U.S. based clinical sites," said George Lasezkay, Pharm.D., J.D., Clearside's President and Chief Executive Officer. "Multiple participants have been enrolled and we have initiated the randomization of participants to receive either CLS-AX or aflibercept one month after they received the first loading dose of aflibercept. This study builds upon the promising data from our OASIS trial in which 67% of extension study participants in Cohorts 3 and 4 went at least 6 months without additional treatment. CLS-AX has the potential to be a twice-a-year treatment for wet AMD, which could reduce the onerous treatment burden for patients who currently require more frequent dosing and numerous office visits with existing approved drugs. We expect to report topline data in the third quarter of 2024," concluded Dr. Lasezkay.

07:13 EDT Parex Resources abandons Chirimoya exploration well at VIM-43 - Parex Resources reports that with testing completed, it has abandoned the Chirimoya exploration well at VIM-43. As previously announced, Parex reached the Chirimoya exploration wells' target depth of approximately 17,500 feet. Following open hole evaluation, including logging operations, the Company made the decision to case and test the well. All three prospective zones were evaluated and confirmed that the potential reservoirs had no economic hydrocarbons. The Chirimoya exploration well was the first prospect in a three well 2023 big 'E', high-impact exploration program. The Northern Llanos Arauca-8 well at Arauca and the Llanos Foothills Arantes-1 well at LLA-122 are expected to be spud in Q4 2023.

07:11 EDT Electra Battery announces shipment of recycled nickel-cobalt from refinery - Electra Battery Materials announced the first customer shipment of nickel-cobalt produced at its refinery complex north of Toronto from recycled battery material. Using Electra's proprietary hydrometallurgical process, the nickel-cobalt mixed hydroxide precipitate product was produced in the Company's black mass recycling trial currently underway at its permitted, low-carbon hydrometallurgical refinery...Electra launched its black mass trial at the end of December 2022, with the goal of validating its hydrometallurgical process in a plant-scale setting and testing its refinery equipment.

07:10 EDT BioVie presents data from Phase 2 biomarker study of NE3107 - BioVie announced data from a poster detailing the epigenetic basis for how in a Phase 2 exploratory biomarker study its drug candidate NE3107 may have potentially regulated specific genes in a manner significantly correlated with observed cognitive and biomarker improvements. The poster was presented yesterday at the Alzheimer's Associate's International Conference, AAIC, held in Amsterdam July 16-20, 2023. In the poster presentation, titled Treatment-Induced Epigenetic Modifications in MCI and Probable Alzheimer's, presenters showed how patients with clinical dementia treated with NE3107 for 3 months saw greater than50% reductions in the level of DNA methylation of over 400 CpGs, and that some of these reductions were significantly correlated with observed improvements in various cognitive measures and biomarkers, as described below. 1) 14 CpGs related to anti-inflammatory genes that are significantly correlated with reduction in plasma TNFalpha levels, which is considered to the master regulator of inflammation. 2) 43 CpGs related to antioxidant genes which are significantly correlated with increases in precuneus glutathione levels from magnetic resonance spectroscopy of the brain. Decreased glutathione levels have been shown to be associated with cognitive decline. 3) Numerous CpGs associated with genes related to insulin signaling and antioxidant responses were significantly correlated with volumetric changes in the hippocampus, subcortical grey matter, as well as frontal, temporal, parietal, and occipital lobes. Volumetric changes in the brain have been associated with alterations in cognitive function in patients with MCI and dementia. 4) Numerous CpGs associated with insulin signaling, antioxidants, anti-inflammatory, anti-apoptotic, anti-amyloid, and neurostimulation were significantly correlated to improvements in cognition and traditional biomarkers of AD. In total, nearly 500 significant correlations were found between all the CpGs and cognitive assessments and over 300 significant correlations between CpGs and AD Biomarkers.

07:08 EDT C4 Therapeutics announces inducement grants under Nasdaq listing rule - C4 Therapeutics announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 351,000 shares of the Company's common stock to two new employees, with grants made on July 10 and July 17, 2023. The Inducement Grants were granted as inducements material to these individuals entering into employment with C4T in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grants have an exercise price per share that is equal to the closing price of C4T's common stock on their respective Grant Dates. The Inducement Grants will vest over a four-year period, with 25% of the shares vesting on the first-year anniversary of the employee's start date, and thereafter the remainder of the shares vesting in twelve equal quarterly installments, subject to each employee's continued employment with C4T through each vesting date.

07:08 EDT Compugen wins on PVRIG European patent opposition pursued by GSK, third party - Compugen (CGEN) announced that the broad claims of Compugen's Anti-PVRIG Antibodies for use in treating cancer patent granted by the European Patent Office, which had been under opposition, have been successfully maintained. Oppositions were pursued by GSK (GSK) and an anonymous opponent represented by a third party against EP3258951B1. In an oral proceedings hearing on July 11 2023, the opposition division of the European Patent Office ruled in favor of maintaining the broad claims in the patent as granted to Compugen. The opponents can appeal this decision. "We are delighted with the decision of the opposition division of the European Patent Office ruling in favor of maintenance of the broad claims in the patent as granted, supporting our patent strategy in novel target discovery." said Anat Cohen-Dayag, Ph.D., President, and CEO of Compugen.

07:07 EDT EyePoint reports inducement grants under Nasdaq listing rule - EyePoint Pharmaceuticals announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 14,000 shares of EyePoint Pharmaceuticals common stock to two new employees. The stock options were granted on July 14, 2023. The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint Pharmaceuticals in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of $10.97 per share, the closing price of EyePoint Pharmaceuticals' common stock on July 14, 2023. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee's date of grant and the remainder vesting in equal monthly installments over the following three years. Vesting of the options is subject to the employee's continued service with EyePoint Pharmaceuticals through the applicable vesting dates.

07:06 EDT Ginkgo Bioworks, MoH of Botswana pathogen monitoring program at key ports - Ginkgo Bioworks and the Ministry of Health representing the Government of the Republic of Botswana, announced a pathogen monitoring program at key ports of entry to identify new and emerging variants of SARS-CoV-2. Through this program, Ginkgo's biosecurity and public health unit, Concentric by Ginkgo, will collaborate with the MoH to monitor wastewater and nasal swab samples collected on a voluntary, anonymous basis from arriving international travelers for SARS-CoV-2 surveillance. Ginkgo and the MoH will work together to establish Sir Seretse Khama International Airport as a new node in a global network of pathogen monitoring infrastructure, complementing the insights generated from Concentric's existing travel biosecurity programs at several major international airports. The program builds on Ginkgo's previously announced MOU to develop and implement biosecurity capabilities in Botswana, and will also incorporate pathogen monitoring at land borders, at municipal wastewater treatment works, and for livestock in the food system.

07:06 EDT Americas Gold and Silver provides Q2 production results - Americas Gold and Silver provided its Q2 production results. Q2 consolidated attributable silver production increased by 92% year-over-year and 15% quarter-over-quarter totaling approximately 0.57M ounces compared with approximately 0.30M ounces in Q2-2022 and 0.50M ounces in Q1. Consolidated attributable silver equivalent production in Q2 was approximately 1.3M ounces compared with approximately 1.2M ounces in Q1 and 1.3M ounces in Q2-2022. Production guidance for 2023 remains unchanged with consolidated attributable silver production expected to range between 2.2M and 2.6M ounces and consolidated attributable silver equivalent production expected to range between 5.5M and 6M ounces. The company successfully installed the Galena Hoist which is now operational as of the end of Q with only shaft repair remaining before final certification can be obtained. "The Company continued the strong momentum from Q1-2023 and delivered another solid production quarter in Q2-2023, resulting in a significant increase in silver production quarter-over-quarter and year-over-year. Production in the second half of the year is expected to be higher than the first half of the year," stated Americas President and CEO Darren Blasutti. "The Galena Hoist was successfully installed by the end of the quarter with only shaft repair remaining on a part of the shaft. The Galena Hoist is expected to positively impact the Galena Complex operations for many years to come."

07:05 EDT BioLineRx initiates Phase 2 trial in first line metastatic pancreatic cancer - BioLineRx announced the initiation of a randomized, investigator-initiated Phase 2 clinical trial in first line metastatic pancreatic cancer based on preliminary data from the single-arm pilot phase. The combination drug trial includes the investigational candidate motixafortide. Sponsored by Columbia University, the amended study will modify a single-arm trial whose original design called for expansion to an additional 30 patients if data from a pilot phase of 10 patients was encouraging. The amended randomized study will compare combination treatment with the company's CXCR4 inhibitor, a PD-1 inhibitor, and chemotherapy to chemotherapy alone in a larger number of patients

07:03 EDT MediPacific to acquire Pardes Biosciences for $2.02-$2.19 per share in cash - Pardes Biosciences has entered into a definitive merger agreement whereby MediPacific will acquire Pardes for a price per share of not less than $2.02 in cash and an additional cash amount of not more than $0.17 per share, with the final price per share being based on the amount of the Company's net cash at closing, plus a non-tradeable contingent value right associated with any future monetization of its COVID-19 antiviral portfolio and related intellectual property. Following a thorough review process conducted with the assistance of its legal and financial advisors, a Special Committee of the Pardes Board of Directors, consisting solely of independent and disinterested members of the Pardes Board of Directors, determined that the acquisition by Purchaser-of which Foresite Capital Management, a significant Pardes stockholder, and Dr. James Tananbaum, a founding partner of Foresite Capital and a director on the Pardes Board of Directors, are the controlling stockholders-is in the best interests of all Pardes stockholders not affiliated with Foresite, and has unanimously recommended the merger agreement to the Pardes Board of Directors. Based upon the recommendation of the Special Committee and with the assistance of legal and financial advisors, the disinterested members of the Pardes Board of Directors have unanimously determined that the acquisition by Purchaser is in the best interests of all Pardes stockholders not affiliated with Foresite and have unanimously approved the merger agreement. Pursuant to the terms of the merger agreement, a subsidiary of Purchaser will commence a tender offer by July 28, 2023 to acquire all outstanding shares of Pardes for a price per share of not less than $2.02 in cash and an additional cash amount of not more than $0.17 per share at closing plus the CVR representing the right to receive 80% of the net proceeds payable from any license or disposition of Pardes' programs and assets effected within five years of closing. Closing of the tender offer is subject to certain conditions, including the tender of Pardes shares representing at least a majority of the total number of outstanding shares not held by affiliates of the Purchaser as of immediately following the consummation of the offer; Pardes having at least $125 million of net cash at closing; and other customary conditions. Immediately following the closing of the tender offer, Pardes will merge with a subsidiary of the Purchaser, and all remaining shares not tendered in the offer, other than dissenting shares and shares held by Purchaser or Pardes, will be converted into the right to receive the same cash and CVR consideration per share as is provided in the tender offer. The acquisition is expected to close in the third quarter of 2023.

07:03 EDT ViewRay files voluntary Chapter 11 petitions - ViewRay announced that it and certain of its subsidiaries filed voluntary petitions for relief under Chapter 11 of Title 11 the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware. The Company further disclosed that it intends to pursue a sale of its business under Section 363 of the Bankruptcy Code, including a sale of all or a portion of the company's assets, while continuing to support its customers during the Chapter 11 process. To facilitate this process, in addition to having the use of its sufficient existing cash reserves, the company has received a commitment of approximately $6M in debtor-in-possession financing from MidCap Financial Services, LLC. Following court approval, the company expects this financing to provide the necessary liquidity to support operations during the Chapter 11 process. Alongside these efforts, the company is strategically managing inventory to maintain MRIdian MRI-guided radiation therapy systems at customer sites across the globe. The company has filed a variety of "first day" motions containing customary relief intended to assure the company's ability to continue its ordinary course operations, such as continuing to service its customers and honor its obligations to its remaining employees, following an additional reduction in force, as the company begins its efforts to effectuate the sale of its assets. On July 15, 2023, prior to filing the Petitions, Phillip Spencer and Gail Wilensky, Ph.D., advised the Board of Directors of the company of their resignations from the Board. Subsequently, on July 15, 2023, Scott Drake ceased to serve as the CEO of the company, and transitioned to a continuing role as a director of the company. The company has appointed Paul Ziegler as CEO of the company, effective July 15, 2023. Ziegler, who had been the Chief Commercial Officer of the company, has also been appointed to the Board as a director. The Board also decreased the size of the Board from nine to seven directors. In addition, the company has appointed Sanket Shah as Senior Vice President, General Counsel of the company, effective as July 15, 2023. Shah has been at the company since 2019, most recently acting as Vice President, Deputy General Counsel.

07:01 EDT Tonix announces agreement, initiation of Phase 2 trial of TNX-1900 - Tonix Pharmaceuticals announced that the first participant has been enrolled in a Phase 2 investigator-initiated, proof-of-concept study of TNX-1900 for enhancing social safety learning in social anxiety disorder. Tonix entered into an agreement with the University of Washington to examine the potential role of TNX-1900 with Angela Fang, Ph.D., Assistant Professor, Department of Psychology, University of Washington as the principal investigator. "We are excited to collaborate with the University of Washington and Dr. Fang on the development of TNX-1900 for social anxiety disorder," said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. "In the past decade, there has been an increase in studies examining oxytocin's effects on social cognition and behavior in animals and humans due to translational discoveries showing that intranasal oxytocin appears to reach central nervous system targets. Specifically, evidence suggests that oxytocin may enhance the importance of social cues or have anti-anxiety properties. These studies have shown that intranasal oxytocin may hold therapeutic promise for psychiatric disorders involving social deficits. TNX-1900 is a proprietary formulation of oxytocin that contains magnesium, which Tonix has shown in animal models potentiates the action of oxytocin at oxytocin receptors and potentially improves the consistency of treatment by reducing paradoxical high-dose inhibition."

06:49 EDT Virgin Galactic announces crew of 'Galactic 02' spaceflight - Virgin Galactic Holdings announced the crew of its seventh spaceflight and second commercial spaceflight, 'Galactic 02,' which will fly three private passengers to space, achieving several historical milestones and furthering the company's mission of broadening access to space. VSS Unity will carry 80-year-old Jon Goodwin, Olympian and early Virgin Galactic ticket holder, as well as Keisha Schahaff and Anastatia Mayers, a Caribbean mother-daughter duo who won their seats in a draw that raised funds for non-profit Space for Humanity. The flight window opens August 10.

06:47 EDT Scorpio Tankers announces purchase of shares in open market - Scorpio Tankers has recently repurchased 838,050 of its common shares in the open market at an average price of $43.93 per share. There is $213.2M of remaining availability under the company's 2023 Securities Repurchase Program as of July 17.

06:35 EDT Eneti announces contract awards for Seajacks subsidiary - Eneti announced that Seajacks UK Limited, a wholly-owned subsidiary of the company, has signed two new contracts in the offshore wind sector in NW Europe for between 62 and 82 days of employment for two of its NG2500X-class vessels that will generate between approximately $5.2M-$6.7M of revenue in 2023.

06:33 EDT Willis Lease announces new Power-to-Liquid SAF project - Willis Lease Finance announced an innovative project to develop and produce Power-to-Liquid Sustainable Aviation Fuel. Most notably, the company and its subsidiary, Willis Sustainable Fuels Limited, along with financial and strategic partners, are advancing plans toward a new SAF refinery in northeastern England.

06:14 EDT Clear Channel Outdoor enters exclusive discussion to sell France business - Clear Channel Outdoor announced that it has entered into exclusive discussions to sell its business in France to Equinox Industries, a Paris-based industrial holding company that makes long-term majority equity investments. In addition, Didier Quillot, a senior advisor to Equinox, would participate alongside Equinox in the proposed transaction and would be appointed non-executive chairman of Clear Channel France upon completion. The parties are aiming to complete the proposed transaction in Q4, subject to an information and consultation process with Clear Channel France's employee works council, execution of a share purchase agreement and the satisfaction of customary closing conditions. The transaction is not subject to regulatory approval. The company is not disclosing financial details of the contemplated transaction at this time, and investors should not assume any particular terms. The company's board of directors continues its reviews of strategic alternatives for the company's other European businesses. There can be no assurance that the strategic reviews will result in any additional transactions or particular outcomes. The company has not set a timetable for completion of these processes and may suspend these processes at any time.

06:07 EDT Panbela Therapeutics issued new patent in Australia - Panbela Therapeutics announced an Issue Notification for the Australian patent 2019213664 titled "METHODS FOR PRODUCING (6S,15S)-3,8,13,18- TETRAAZAICOSANE-6,15-DIOL". This patent, developed in collaboration with Syngene International Ltd., an integrated research, development, and manufacturing services company, claims a novel process with a reduced number of synthetic steps from seventeen to six to produce SBP-101, a lead investigational product. The patent is valid until 2039.

06:05 EDT Huntington Ingalls, Babcock International Group enter strategic partnership - HII (HII) and Babcock International Group (BCKIF) have entered into a strategic agreement to collaborate on naval and civil nuclear decommissioning and construction opportunities in the U.K. and U.S. HII and Babcock will apply their complementary capabilities to existing nuclear decommissioning contracts for U.S. ships and U.K. submarines, to share best practices and provide the opportunity to upskill and enhance both organizations' capability for the benefit of the U.S. and U.K. programs. The Memorandum of Understanding also identifies opportunities for cooperation in civil nuclear, including power plant and component design, fabrication and construction in North America and the U.K. For Babcock, this will include leveraging the capability of its wholly-owned subsidiary, Cavendish Nuclear, a leader in the U.K. nuclear civil industry across the nuclear lifecycle.

06:02 EDT Stratasys board unanimously rejects revised offer from Nano Dimension - Stratasys (SSYS) announced that its Board of Directors, after consultation with its independent financial and legal advisors, unanimously determined that the revised partial tender offer announced by Nano Dimension (NNDM) on July 10, 2023 to acquire ordinary shares of Stratasys for $24.00 per share in cash is misleading, coercive, substantially undervalues the company as a whole and is NOT in the best interests of all Stratasys shareholders. Accordingly, the Board unanimously recommends that shareholders reject the revised partial offer, deliver a Notice of Objection against the partial offer and do NOT tender their Stratasys shares in the partial offer.

05:22 EDT Zai Lab, Argenx announce ADHERE study met primary endpoint - Zai Lab (ZLAB) and Argenx (ARGX) announced topline results from the ADHERE study evaluating Vyvgart in adults with chronic inflammatory demyelinating polyneuropathy, or CIDP. The study met its primary endpoint, demonstrating a significantly lower risk of relapse with Vyvgart Hytrulo compared to placebo. Detailed data from ADHERE will be presented at an upcoming medical meeting. ADHERE is the largest clinical trial of CIDP patients to date, enrolling adults who were treatment naive or currently on immunoglobulin therapy or corticosteroids. The trial consisted of a run-in period where current treatment was stopped followed by an open-label Stage A, after which responders to VYVGART Hytrulo advanced to a randomized, placebo-controlled Stage B. Overall, 322 patients enrolled in Stage A and received treatment with Vyvgart Hytrulo. In total, 67% demonstrated evidence of clinical improvement after a run-in withdrawal period based on the Inflammatory Neuropathy Cause and Treatment Disability Score, the Inflammatory Rasch-built Overall Disability Scale or grip strength; 70% demonstrated ECI excluding patients ongoing in Stage A at the time of the 88th event who did not have the full opportunity to achieve a response; 78% demonstrated ECI in a sensitivity analysis of patients who received at least four injections to reach the full IgG-lowering effect of Vyvgart Hytrulo. Response rates similar across all prior CIDP medication subgroups with consistent efficacy on INCAT, I-RODS and grip strength 221 responders from Stage A entered Stage B, where the primary endpoint was the relative risk of relapse based on time to relapse on the INCAT Disability Score. Vyvgart Hytrulo significantly reduced the risk of CIDP relapse compared to placebo Primary endpoint was met; Vyvgart Hytrulo demonstrated a 61% reduction in the risk of relapse compared to placebo based on time to the first adjusted INCAT deterioration of greater than or equal to1 point. Vyvgart Hytrulo patients had a lower relapse rate compared to placebo at Week 24 (26% versus 54%) and Week 48. Vyvgart Hytrulo patients experienced longer time to relapse compared to those on placebo with a rapid separation of the Kaplan-Meier curves beginning at Week 4 and sustained through Week 48. Vyvgart Hytrulo patients demonstrated a clinically meaningful mean improvement of 7.7 points on I-RODS and 12.3kPa on grip strength in Stage A. This clinically meaningful benefit was maintained in Stage B by treated patients and lost in placebo patients. Clinical benefit observed across all efficacy scales and patient subgroups, regardless of prior therapy. Vyvgart Hytrulo was well-tolerated with a safety profile that is consistent with prior clinical trials and the known profile of Vyvgart. The most frequent treatment-related adverse event was injection site reactions, which occurred in a lower percentage of patients than previous Vyvgart Hytrulo trials. All ISRs were mild to moderate and resolved over time. Zai Lab has an exclusive license agreement with argenx for the development and commercialization of Vyvgart and Vyvgart Hytrulo in Greater China. Through this agreement, Zai Lab dosed the first patient in the Greater China portion of the global registrational ADHERE trial in November 2021, and contributed a significant number of patients into this trial.

05:08 EDT Paysafe announces new partnership with Betr - Paysafe announced a new partnership with Betr, the micro-betting app from American professional boxer and social media influencer Jake Paul. The first phase of a multi-state deal sees Paysafe enable Betr's customers in Ohio and Massachusetts to fund micro-bets and traditional wagers using their debit card. Now, when Ohio and Massachusetts players want to make a micro-bet or a standard sports-bet with the Betr iOS or Android apps on their smart phone or tablet, they can securely deposit into their account using their debit card, with all transactions processed in seconds by Paysafe's own payment gateway. Betr's connectivity to the Paysafe platform will allow the operator to access the payment provider's complete range of alternative payment methods, including its digital wallet and eCash solutions. The partnership is expected to extend into additional U.S. states, as Betr launches in new gaming jurisdictions.